• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Orchard Therapeutics plc

    2/5/24 2:39:49 PM ET
    $ORTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ORTX alert in real time by email
    15-12G 1 d731893d1512g.htm 15-12G 15-12G
    OMB APPROVAL  
    OMB Number:   3235-0167   
    Expires:   July 31, 2024   
    Estimated average burden  
    hours per response   1.50   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number 001-38722

     

     

    ORCHARD THERAPEUTICS PLC

    (Exact name of registrant as specified in its charter)

     

     

    245 Hammersmith Road, London W6 8PW, United Kingdom; +44 (0) 203 808-8286

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    American Depositary Shares, each representing one ordinary share, nominal value £0.10 per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

       ☒

    Rule 12g-4(a)(2)

       ☐

    Rule 12h-3(b)(1)(i)

       ☒

    Rule 12h-3(b)(1)(ii)

       ☐

    Rule 15d-6

       ☐

    Rule 15d-22(b)

       ☐

    Approximate number of holders of record as of the certification or notice date: One (1) holder

    Pursuant to the requirements of the Securities Exchange Act of 1934 (Name of registrant as specified in charter) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date:   

    February 5, 2024

         By:   

    /s/ Frank E. Thomas, President and Chief Operating Officer

     

    SEC 2069 (08-11)   Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

    Instruction: This form is required by Rules 12g-4, 12h-3, 15d-6 and 15d-22 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.

     

     

     

    Get the next $ORTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORTX

    DatePrice TargetRatingAnalyst
    12/29/2021$12.00 → $9.00Overweight
    Cantor Fitzgerald
    11/16/2021Neutral → Underweight
    JP Morgan
    11/5/2021$15.00 → $13.00Outperform
    Oppenheimer
    8/18/2021Overweight → Neutral
    JP Morgan
    More analyst ratings